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FcRn, resembling a major histocompatibility complex class I molecule with a closed peptide cleft, is an
intracellular molecule that binds endocytosed albumin and IgG by a pH-dependent mechanism, diverting
them from degradative fates and moving them out of the cell. The turnover of both of these important plasma
proteins is thus regulated, as discussed by Schmidt and colleagues in this issue of Structure.Had FcRn not risen over the course of
evolution, we would need a liver half again
as large and an immune system two and
one-half times its current size. This is a
fatuous but graphic way of describing
what we have learned from kinetic molec-
ular modeling. We found that FcRn,
situated in the membrane of acidic endo-
somes of many cells, salvages from
constitutive intracellular degradation half
the amount of albumin as is made each
day by the liver and one and one-half
times the amount of IgG produced each
day by the immune system. Figure 1 sche-
matically shows whole-body turnover
rates for IgG and albumin in grams per
day for a 70 kg human, using data derived
from published turnover studies in hypo-
albuminemic, hypogammaglobulinemic,
FcRn-deficient, and normal subjects.
Conclusions are similar in the mouse. In
short, the concentrations of the two major
proteins of plasma, albumin and IgG, are
both maintained, remarkably, by a single
molecule, FcRn, that diverts them from
an intracellular degradative fate.
Only by fits and starts has FcRn
become known to us. It was first imagined
in the 1940s by Rogers Brambell, whowas asking how IgG moved across the
yolk sac from maternal to fetal blood,
thus providing the newborn rabbit with
its mother’s full complement of protective
IgG antibody. He found that all blood
proteins entered the endoderm trans-
porter cell, but only IgG came out. A
similar transport system across the
neonatal small intestine of rats and mice
provided the neonate with its mother’s
antibody-mediated immunity. The work
of others at the time, who were studying
the metabolism of serum proteins,
showed that the fractions of circulating
IgG and albumin catabolized per unit
time were related directly to their plasma
concentrations, whereas all other proteins
showed an indirect relationship or no rela-
tionship. Unifying these sets of data on
transport and catabolism for IgG (but
curiously ignoring albumin), Brambell pro-
posed a single model in which an intracel-
lular receptor (now FcRn) intercepted IgG
after its nonspecific pinocytosis and
moved it specifically out of the cell, trans-
porting it toward the offspring or salvaging
it from degradation (Brambell et al., 1964).
It remained for others to propose another
albumin-specific receptor that workedjust like the Brambell receptor (Schultze
and Heremans, 1966).
The IgG-transporting receptor was
purified from neonatal rat gut by affinity
to immobilized IgG at low pH (Simister
and Rees, 1985), the acid dependency
of receptor binding having been stumbled
upon earlier by a systematic biochemical
evaluation (Jones and Waldmann, 1972).
It was promptly characterized as a major
histocompatibility complex class I-like
molecule and named FcRn, from Fc
Receptor from neonatal rat gut. A series
of careful biochemical studies ensued,
attributing the high affinity at low pH and
the nil affinity at physiologic pH to critical
histidine residues. Ultimately, the co-
crystal structure of the truncated soluble
FcRn with the Fc piece of IgG was
analyzed, appearing on the cover of
Nature in 1994 (Burmeister et al., 1994).
Avoiding the closed peptide cleft, the
ligand sat on the shoulder of the receptor
interacting with both chains of the hetero-
dimer. The receptor likely functioned as a
dimer, with each unit binding an IgG
heavy chain.
Although Brambell’s unification model
indicated that the transporter FcRn would2013 Elsevier Ltd All rights reserved 1907
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Figure 1. Schematic Representation of IgG and Albumin Turnover in
Humans at Normal Physiological Conditions
Shown are the absolute catabolic rates (2.7 and 13.2 g/day); the FcRn-medi-
ated recycling rates back to plasma (3.8 and 5.9 g/day); the production rates
(2.7 and 13.2 g/day), the same as catabolic rates to maintain the steady-state
levels; and intravascular pool sizes (35.6 and 122 g), which are defined as the
product of steady-state plasma concentration and the volume of distribution
of the protein. The figure is drawn to scale: areas for mass in plasma and arrow
widths for rates. Taken from Kim et al. (2007) with permission from Elsevier.
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Previewsalso salvage IgG from degra-
dation, this latter feature lay
fallow until the introduction
of the b2-microglobulin knock
out mouse strain (Spriggs
et al., 1992). The IgG defi-
ciency of this strain was ulti-
mately attributed to an absent
FcRn and a shortened IgG
half-life (Ghetie et al., 1996;
Junghans and Anderson,
1996; Israel et al., 1996).
That this strain was also
hypoalbuminemic because
of a short albumin half-life
was ignored until we acci-
dentally found that albumin
bound to FcRn in aqueous
solution. BSA co-purified in
roughly molar equivalents
with soluble FcRn during the
course of affinity adsorption
on IgG (Chaudhury et al.,
2003). It was clear that both
albumin and IgG could bind
truncated FcRn at distant
sites on the receptor, without
cooperation or interference,
at a presumptive molar ratio
of 1:2:2::IgG:FcRn:albumin
(Chaudhury et al., 2006).
Binding at both sites showeda similar pH dependence. Histidine 166,
which was essential for albumin binding,
appeared surrounded by a dozen or
more conserved residues, placing the al-
bumin binding site over a wide area
centering on the A pocket of the peptide
cleft. The detergent sensitivity of the
interaction and its positive entropy
implied hydrophobic bonding. The third
domain of albumin was responsible for
most of the interaction. Searching for hu-
mans with the phenotype of the FcRn-
knock out mouse strain, we discovered
in the literature a family with low IgG
and albumin concentrations. Their FcRn
deficiency was the result of a mutant
b2-microglobulin gene (Wani et al., 2006).
Thus, early observers were correct
(Schultze and Heremans, 1966); there
was indeed an albumin receptor, but
it was part of the IgG receptor FcRn. It
was noteworthy that catabolism and
transport of the two major plasma pro-1908 Structure 21, November 5, 2013 ª2013teins of the body, albumin and IgG, were
performed by a single receptor.
At this point, it seemed to us that no
more big questions could be answered
without resolution of the co-crystal struc-
ture, which had eluded us since 2003.
We still need to know why albumin
cannot be shown to move from mother
to fetus. Are lipids or other albumin-fam-
ily proteins inhibiting? Why has it not
been possible to study albumin intracel-
lular transport in vitro? Does FcRn
modify the offloading of albumin ligands
at their destinations? What are the impli-
cations of the apparent hydrophobic
nature of the albumin binding site of
FcRn, and how is the pH-sensitive histi-
dine accommodated in the structure?
The lower fractional salvage rate of albu-
min compared with IgG would suggest
that albumin would not be the linker of
choice for therapeutically prolonging
half-lives of drugs. Would the co-crystalElsevier Ltd All rights reservedstructure suggest strategies
to obviate this disadvantage?
For answers to these ques-
tions and others, we look for-
ward to studying the analysis
by Schmidt et al. (2013) of
the structure of the co-crystal
of FcRn and albumin in this
issue of Structure.
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